Porton Advanced Solutions (Porton Advanced) is a Cell and Gene Therapy (CGT) CDMO. We provide end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services to meet clients’ therapeutic product needs at pre-clinical, clinical, and commercial stages.
Our dedicated process and analytical development teams have established robust platform-based USP/DSP and GMP manufacturing capability and capacity, as well as proprietary technologies to further empower our clients’ successes.
Our services include gene and cell engineering discovery research and technology licensing, process development and analytical development, testing, drug substances (DS) and drug products (DP), and cGMP manufacturing across plasmids, cell therapy, gene therapy, virotherapy, and mRNA-based therapeutic platforms.
To accelerate the development and manufacture of advanced medicines to deliver life-changing benefits to patients.
To be a leading global CGT CDMO, supporting our partners in delivering quality advanced medicines through innovation, care, and commitment.
Our experienced management team brings decades of industry experience and a track record of success in drug discovery, development and commercialization.
Our team is dedicated to helping our customers and we share in their goals to accelerate the delivery of advanced therapies to patients worldwide.
We work hard, we collaborate, we share knowledge and expertise and learn from one another, and we respect and protect our clients’ intellectual property, to be able to deliver the highest quality service.
If you are interested in one of our vacancies, or would like to share a speculative application, please submit a cover letter and CV.
Porton Advanced strives to build a positive and supportive corporate culture for our employees. It is our Mission to support the development of breakthrough therapeutics that benefit patients, and this commitment brings responsibilities for both the company and our employees.
We understand that our employees are our greatest assets, and to maintain a great working environment, we encourage collaboration, respect, hard work, and social responsibility.
©2022 Porton Advanced Solution Ltd. All Rights Reserved. Instinctif Partners
The repeatability study of selected samples at certain dilution levels showed great repeatability with a CV value of less than 10%.
Case study
Assays
Case Study
mRNA purity –AUC effectively distinguishes the different components in an mRNA sample, such as truncated mRNA (Peak 1), monomeric mRNA (Peak 2), long-chain mRNA, and mRNA aggregates (Peak 3& 4).
Figure 8
Lentivirus titer produced in two suspension cell production system:
A. Viral titer from a leading commercial packaging system. B. Viral titer from Porton Advanced’s PTLV-SMART packaging system.
Figure 4
T cell transduction with lentivirus produced using our HEK293T system. T cells are infected with lentivirus at different MOI. CAR-T cell percentages were measured by FACS.
Figure 20
Figure 7
Figure 5
Figure 6
An AAV variant from our library screening showed that the virus was able to package a 6.1kb genome.
Figure 19
AAV variants enriched in different tissues during library screening. AAV libraries were prepared and injected into the hosts. After two weeks, tissues were harvested and viral genomes were isolated for PacBio sequencing. Viral genomes were clustered against different tissues.
Figure 18
Separation of empty and full rAAV by anion chromatography. A: AEX result of rAAV5; B: AEX result of rAAV9
Figure 3
CAR expression with escalated MOI using PTLV-SMART platform. Activated T cells transduced with escalated MOI, and FACS employed to demonstrate CAR expression post-7 days culture in G-Rex.
Figure 1
Time course of CAR transduction rates of CD3 T cells and cell viability during manufacturing in two cases. T-cells transduced with lentivirus analyzed by flow cytometry to detect CAR-positive or Protein L-positive cell ratio. T-cells expressed CAR stably in the period of CAR-T cell growth with high cell viability.
Figure 2
